Effect of Omega-3 Long Chain Polyunsaturated Fatty Acids (n-3 LCPUFA) Supplementation on Cognition in Children and Adolescents: A Systematic Literature Review with a Focus on n-3 LCPUFA Blood Values and Dose of DHA and EPA

Inge S. M. van der Wurff, Barbara J. Meyer, Renate H. M. de Groot*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Citations (Web of Science)

Abstract

Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) supplementation in the cardiovascular field is effective if a certain Omega-3 index (O3I) is achieved or the daily n-3 LCPUFA dose is high enough. Whether this applies to studies on cognition in children and adolescents is unclear. The aims of the current review were to investigate whether: (1) a certain O3I level and (2) a minimum daily n-3 LCPUFA dose are required to improve cognition in 4-25 year olds. Web of Science and PubMed were searched. Inclusion criteria: placebo controlled randomized controlled trial; participants 4-25 years; supplementation with docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); assessing cognition; in English and >= 10 participants per treatment arm. Thirty-three studies were included, 21 in typically developing participants, 12 in those with a disorder. A positive effect on cognitive measures was more likely in studies with an increase in O3I to >6%. Half of the studies in typically developing children with daily supplementation dose >= 450 mg DHA + EPA showed improved cognition. For children with a disorder no cut-off value was found. In conclusion, daily supplementation of >= 450 mg DHA + EPA per day and an increase in the O3I to >6% makes it more likely to show efficacy on cognition in children and adolescents.

Original languageEnglish
Article number3115
Number of pages25
JournalNutrients
Volume12
Issue number10
DOIs
Publication statusPublished - Oct 2020

Keywords

  • adolescents
  • children
  • long-chain polyunsaturated fatty acid
  • cognition
  • Omega-3 Index
  • DEFICIT HYPERACTIVITY DISORDER
  • ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
  • RICH FISH-OIL
  • PLACEBO-CONTROLLED INTERVENTION
  • DOCOSAHEXAENOIC ACID
  • DOUBLE-BLIND
  • OMEGA-3-FATTY-ACID SUPPLEMENTATION
  • SUSTAINED ATTENTION
  • HEALTHY-CHILDREN
  • CONTROLLED TRIAL

Cite this